Founded in 2006, ChemExpress focuses on providing small molecule and new modalities CDMO services for both pharmaceutical and biotech clients. Our comprehensive CRO & CDMO platform is engaged in the research and development, manufacturing and supply of regulatory starting materials, novel building blocks, intermediates, reference compounds, APIs and drug products. We are a one-stop service platform to support our client’s projects from early drug discovery, process development to commercialization. Over the past 17 years, we have established a state-of-the-art QC/QA system aligning with ICH guidelines for pharmaceutical manufacturing. We provide our clients with high-quality products and CMC services across the entire life-cycle of drug development.
Year Established: 2006
Total Assets(USD): 500,000 to 99,999,999
Total Number of Staff: more than 1000
Main Competitive Advantages: Brand Name,International Approvals/Standards,Experienced R&D Staff,Delivery Term,Production Capacity,Large Product Line,Contract Manufacturing (CRO,CMO),Buyers' Specifications Accepted,Reputation,Quality Service
Business Type: Manufacturer
R&D Capacity: OEM,ODM,Own Brand
Annual Turnover(USD) : 500,000 to 99,999,999
Main Sales Markets : Western Europe,Eastern Europe
Subscribe to the latest newsletter of Virtual Expo Connect